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SI Materials and Methods 
 
Antibodies and Other Reagents. Antibodies to the following antigens were used for 
immunoblotting: anti-hsc82 antibody (Abcam, ab30920); anti-hsv antibody (Sigma, H6030); 
anti-flag M2 mouse monoclonal antibody (Sigma, F1804); anti-c-Myc-9E10 monoclonal 
antibody (Sigma, M5546); and anti-ha tag rabbit monoclonal antibody (Sigma, H6908). 
Secondary antibodies for immunoblotting were Li-Cor IRDye-conjugated goat anti-mouse 
800CW (Li-Cor, C60405-05) or anti-rabbit 680RD (Li-Cor, C51104-08). Affinity-purified rabbit 
antibody to S. cerevisiae Ubr1 was produced as described previously (1, 2). Fluorescence 
patterns were detected and quantified using Odyssey-9120 (Li-Cor, Lincoln, NE).  
Affinity-purified rabbit antibody to S. cerevisiae Naa10 was produced by immunizing 
two rabbits (at Covance, Inc., Sherman Oaks, CA) with ~5 mg of purified Naa10. The latter was 
produced by expressing His10-Ub-Naa10 in E. coli from pJO162 (Table S2) and purifying 
untagged Naa10 by affinity chromatography and the cleavage by a deubiquitylase as described 
previously (3). Antisera to Naa10 were purified by TALON affinity chromatography (Clontech), 
with immobilized Naa10. The resulting antibody was then further purified through “negative” 
selection using a nitrocellulose membrane with immobilized extract from naa10∆ S. cerevisiae 
cells. For immunoblotting results with this antibody, see Figure 3A, lanes 11-13. 
Other reagents included “complete protease inhibitor cocktail” tablets (Roche, 
11697498001); protease inhibitor cocktail “for use with fungal and yeast extracts” (Sigma, 
P8215); protease inhibitor cocktail “for use in purification of Histidine-tagged proteins” (Sigma, 
P8849); phenylmethylsulfonyl fluoride ((PMSF) Sigma, P7626); cycloheximide (Sigma, C7698); 
tetracycline hydrochloride (Sigma, T3383); and DNase I (Roche, 11284932001), human 
rhinovirus (HRV) 3C protease (Thermo Fisher, 88946). 
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Yeast Strains, Media, and Genetic Techniques. The S. cerevisiae strains used in this 
work are described in Table S1. Standard techniques (4) were used for strain construction and 
transformation. S. cerevisiae JOY379, JOY439, JOY440, JOY441, JOY442, JOY443, JOY468, 
JOY487, JOY498, JOY505 and JOY529 were constructed using the PCR-based gene targeting 
method (5) and pFA6a-KanMX6, HphNT1 or NatNT2 modules (6). S. cerevisiae JOY512, 
JOY513 and JOY514 were constructed by extending, using standard recombination methods (6), 
the endogenous CHK1 open reading frame (ORF) in the strains BY4742, CHY271 and JOY379, 
respectively (Table S1), with a sequence encoding nine consecutive c-myc epitope tags from 
either pYM20 or pYM18. S. cerevisiae media included YPD (1% yeast extract, 2% peptone, 2% 
glucose; only most relevant components are cited); SD medium (0.17% yeast nitrogen base, 
0.5% ammonium sulfate, 2% glucose); and synthetic complete (SC) medium (0.17% yeast 
nitrogen base, 0.5% ammonium sulfate,2% glucose), plus a drop-out mixture of compounds 
required by specific auxotrophic strains.  
 
Construction of Plasmids. The plasmids used in this study are described in Tables S2. 
To construct the DHFR-reference part of the PRT vector pJO622, the multipartite PTDH3 
promoter, containing three tetracycline (Tc) aptamers, was amplified from PTDH3-tc3-3×ha (Table 
S2) (7), and the flagDHFRha ORF was amplified from pJO379. PCR products were digested with 
SacI/EcoRI and EcoRI/XhoI, respectively, and ligated into SacI/XhoI-cut pRS413-Met25. The 
PRT-based pJO624 (Table S2), used throughout this study, was constructed by amplifying 
PTDH3-tc3, S. Cln3-3-flag, the cyc1 terminator, and PTDH3-tc3-flagDHFRha from pJO622 
(Table S2). The resulting DNA was digested with SacII/AscI, AscI/NotI, NotI/FseI and 
FseI/XmaI respectively, and ligated into SacII/XmaI-cut pRS313, yielding pJO624 (Table S2). 
For constructing a Chk1-expressing plasmid, the S. cerevisiae CHK1 ORF (amplified 
from S. cerevisiae genomic DNA) was digested with AscI/BglII and was ligated into 
AscI/BamHI-cut pJO624, yielding pJO630 (Table S2). Otherwise identical plasmids encoding 
N-terminal mutants of Chk1 were produced using PCR, with a forward primer that contained a 
desired N-terminal mutation. Each PCR-amplified DNA fragment was digested with 
AscI/BamHI and ligated into AscI/BamHI-cut pJO630. Other ORFs used in this study were 
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amplified from S. cerevisiae genomic DNA and cloned by digesting with AscI/BamHI sites, 
followed by the cloning route described above. 
Plasmids expressing UbK48-Y-eK βgal and UbK48-H-eK βgal from PRT-based plasmids, 
were constructed by amplifying DNA segments encoding, respectively, UbK48-Y-eK βgal and 
UbK48-H-eK βgal from pJO746 and pJO747 (Table S2). The resulting DNA fragments were 
digested with AscI/BamHI and ligated into AscI/BamHI-cut pJO699, yielding pJO752 and 
pJO753 (Table S2). 
For split-Ub assays, full-length as well as C-terminally truncated Chk1, Hsc82, Ufd4 and 
Ubr1 ORFs were amplified from S. cerevisiae genomic DNA using appropriate primers that 
contained (asymmetric) SfiI sites at both ends. The resulting DNA fragments were digested with 
SfiI and ligated into SfiI-cut pDHB1 or pPR3-N (Table S2). To construct plasmids for two-hybrid 
assays, the full length S. cerevisiae UBR1 ORF, and either full-length or C-terminally truncated 
Chk1-encoding ORFs were cloned into the pDonor/Zeo via the BP recombination reaction of the 
Gateway system (8) that included the Gateway BP clonase II enzyme mix (Invitrogen). The 
resulting plasmids were pJO781, pJO930, pJO931, and pJO932 (Table S2). Thereafter the LR 
Gateway reaction was carried out with the above plasmids and pGADCg for Gal4-AD 
expression or pGBKT7g for Gal4-DBD expression, using the Gateway LR clonase II enzyme 
mix (Invitrogen). The resulting plasmids were pJO794, pJH024, pJO028, and pJH030, 
respectively (Table S2).  
To construct pJO690, a high copy (2μ-based) plasmid that expressed Ufd4hsv and fUbr1 
from the bidirectional PGAL1/10 promoter, a three-step procedure was used. First, a SacI/XhoI 
fragment was cut from pRS314-Gal1/10 (which contains PGAL1/10), and was ligated into 
SacI/XhoI-cut pRS426-Met25, replacing PMET25 of the original plasmid with the PGAL1/10. The 
resulting plasmid was pJO241. Second, the full-length UBR1 ORF (encoding the N-terminal flag 
tag as well) was amplified from pNTfUBR1 (Table S2) and digested with MfeI/XhoI. The 
resulting DNA fragment was ligated into EcoRI/XhoI-cut pJO241, yielding pJO689. Finally, the 
NotI/FseI fragment of the PCR-amplified UFD4 ORF that was followed by an hsv tag-coding 
DNA sequence, and the FseI/SacII-produced CYC1 terminator (amplified from S. cerevisiae 
genomic DNA were triply ligated into NotI/SacII-cut pJO689, yielding pJO690 (Table S2).  
The plasmids pJO589 and pJO591, which encoded, respectively, S. cerevisiae Ubc4 and 
mono-Ub were constructed by ligating the NcoI/BamHI-digested PCR products of Ubc4 and 
4 
 
mono-Ub ORFs into NcoI/BamHI-cut pET-15b, yielding pJO589 and pJO591, respectively 
(Table S2). pJO663, which encoded His6 followed by the human rhinovirus (HRV) 3C protease 
site and the S. cerevisiae Rad6 moiety, was produced by overlap extension PCR (9). Two 
overlapping DNA fragments, one of them bearing the NcoI site and encoding His6 as well as the 
HRV 3C protease site, and the other one bearing the BamHI site and encoding Rad6 were 
denatured and reannealed, so the they formed a partially duplex DNA that encompassed the 
HRV 3C segment. The resulting PCR-produced fragment was digested with NcoI/BamHI and 
ligated into NcoI/BamHI-cut of pET-11d. The resulting plasmid was pJO663 (Table S2). 
Construction details for other plasmids are available upon request. All final constructs were 
verified by DNA sequencing. 
 
PRT-based cycloheximide-chases and tetracycline-chases. S. cerevisiae were grown 
to A600 of ~ 1.0 in selective liquid media at 30°C, followed by treatment with cycloheximide 
(CHX) or tetracycline (Tc), at the final concentration of 0.36 mM (0.1 mg/ml) or 0.5 mM, 
respectively. At indicated times, cell samples (corresponding to 1 ml of cell suspension at A600 
of ~1.0) were harvested by centrifugation for 5 min at 21,130g. The pellet was resuspended in 
0.8 ml of 2 M Li-acetate for 5 min on ice, followed by centrifugation for 5 min at 21,130g and 
resuspension in 0.8 ml of 0.4 M NaOH for 5 min on ice. The resulting suspension was 
centrifuged for 5 min at 21,130g. The pellet was resuspended in 50 μl of HU buffer (8 M urea, 
5% SDS, 1 mM EDTA, 0.1 M dithiothreitol (DTT), 0.005% bromophenol blue, 0.2 M Tris-HCl, 
pH 6.8) containing 1×protease inhibitor cocktail (Roche) and 1×protease inhibitor cocktail “for 
use with fungal and yeast extracts” (Sigma), and heated for 10 min at 70C. After centrifugation 
for 1 min at 21,130g, 10 l of each supernatant was used to carry out SDS-4-12% NuPAGE 
(Invitrogen), followed by immunoblotting, done as described previously (10, 11), using a 
mixture of anti-ha (1:2,000) and anti-flag (1:2,000) antibodies. Immunoblots were processed 
using secondary antibodies labeled with different fluorophores. Visualized protein bands were 
quantified using the Odyssey-9120 Imaging System (Li-Cor, Lincoln, NE).The near-infrared 
fluorescence range and other features of the Odyssey scanner facilitate quantification of 
immunoblots. 
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35S-pulse-chase assays. These assays were performed largely as described (1, 11-13). 
S. cerevisiae were grown at 30C to A600 of ~1 in 10 ml of SC medium. Cells were pelleted by 
centrifugation, gently resuspended, and washed in 0.8 ml of SD medium with required amino 
acids but without Met and Cys. Cell pellets were gently resuspended again in 0.4 ml of the same 
medium and incubated at 30C for 20 min and thereafter labeled for 2 min at 30°C with 0.16 
mCi of 35S-EXPRESS Met/Cys (Perkin-Elmer). Cells were pelleted again and resuspended in 0.3 
ml of SD medium with required amino acids as well as unlabeled 10 mM methionine and 5 mM 
cysteine. Samples (0.1 ml) were taken at indicated time points, followed by preparation of 
extracts using Mini-Beadbeater-16 (BioSpec) (4 times for 15 sec each, with 5-min intervals on 
ice). The resulting extracts were clarified by centrifugation at 21,000g for 15 min, twice, and 
supernatants were processed for immunoprecipitation, using anti-flag antibody immobilized on 
magnetic beads (Sigma). Immunoprecipitates were analyzed by SDS-4-12% NuPAGE 
(Invitrogen) and autoradiography. 
 
Two-hybrid assays. Yeast-based two-hybrid binding assays (14) were carried out 
largely as described previously (8). S. cerevisiae AH109 (Table S1) was cotransformed with 
pJO794 (expressing NLS-Ubr1-Gal4AD) and either pGBKT7g (expressing Gal4DBD), or pJH024 
(expressing Gal4DBD-Chk11-527), or pJH028 (expressing Gal4DBD-Chk11-502), or pJH030 
(expressing Gal4DBD-Chk11-465) using the lithium acetate method. “AD” and “DBD” refer to 
activation domain and DNA-binding domain, respectively. In both two-hybrid and split-Ub 
assays (described below), the expression of HIS3 (the ultimate readout of both assays), in 
otherwise His- cells, was a function of affinity between test proteins. 
 
Split ubiquitin assays. Yeast-based split-Ub binding assays (15, 16) were carried out 
largely as described previously (8). S. cerevisiae NMY51 (MATa trp1 leu2 his3 ade2 
LYS2::lexA-HIS3 ade2::lexA-ADE2 URA3::lexA-lacZ) (Dualsystems Biotech AG, Schlieren, 
Switzerland), JOY505 (naa10Δ::KanMX6 in NMY51) or JOY529 (naa10Δ::KanMX6, 
ubr1Δ::HphNT1 in NMY51) were cotransformed with split-Ub-based bait and prey plasmids 
(Table S2) using the Li-acetate method. Transformants were selected for the presence of bait and 
prey plasmids during 3 days of growth at 30°C on SC(-Trp, -Leu) medium (minimal medium 
containing 2% glucose, 0.67% yeast nitrogen base, 2% bacto-agar, and complete amino acid 
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mixture lacking Leu and Trp). Single colonies of resulting cotransformants were grown in the 
otherwise identical liquid medium to a near-stationary phase, until A600 of ~1.0. The cultures 
were thereafter serially diluted by 3-fold, and 10 μl samples of cell suspensions were spotted 
onto either double-dropout SC(-Trp, -Leu) plates or triple-dropout SC(-Trp,-Leu,-His), which 
were incubated at 30C for 2-3 days. 
 
Purification of proteins for in vitro ubiquitylation assay. The N-terminally flag-
tagged fUbr1, the C-terminally flag-tagged Ufd4f, and the C-terminally myc-flag tagged full-
length SL-Chk1m−f
1−527 as well as its SL-Chk1m−f
1−502 derivative were overexpressed in protease-
deficient S. cerevisiae SC295 or BY4742 (Table S1) as described previously (17). The resulting 
proteins were purified from cell extracts by affinity chromatography, using anti-flag M2 
antibody-magnetic beads as described previously (18), with slight modifications. S. cerevisiae 
SC295 that expressed fUbr1was grown at 30°C to A600 of ~4 in 8 l of SC(-Leu) medium. BY4742 
cells overexpressed either Ufd4f, or SL-Chk1m−f
1−527, or SL-Chk1m−f
1−502 were grown at 30°C to 
A600 of ~4 in 8 l of SGal(-His) medium (the same as SC(-His) but with 2% galactose instead of 
2% glucose). Cells were harvested by centrifugation, washed once with cold phosphate-buffered 
saline (PBS), and frozen in liquid N2.  
Frozen cell pellets (~25 g) were thawed/resuspended in 150 ml of lysis buffer (10% 
glycerol, 0.5% NP40, 0.2 M KCl, 1 mM PMSF, 5 mM β-mercaptoethanol, 50 mM HEPES, pH 
7.5) containing protease inhibitor mixture (“for use with fungal and yeast extracts”; Sigma). The 
resulting cell suspension was distributed equally into four tubes, and cells were disrupted using 
Mini-Beadbeater-16 (BioSpec; 10 times for 1 min each, with 5-min intervals on ice). The 
resulting suspensions were centrifuged at 11,200g for 30 min at 4C, and each supernatant was 
added to 1 ml of anti-flag-M2 magnetic beads (Sigma), followed by incubation, with rocking, at 
4° C for 2 hr. The beads were collected by magnet, and were washed, sequentially, with 10 ml of 
lysis buffer, with 10 ml of buffer A (10% glycerol, 0.5% NP40, 1 M KCl, 1 mM EDTA, 5 mM 
β-mercaptoethanol, 50 mM HEPES, pH 7.5), and with 10 ml of buffer B (lysis buffer without 
NP40). fUbr1, Ufd4f, SL-Chk1m−f
1−527, and SL-Chk1m−f
1−502, bound to the immobilized anti-flag 
antibody in four different samples, were eluted with 5 ml of buffer C (buffer B containing flag-
epitope peptide (Sigma) at 0.5 mg/ml), and the sample was dialyzed at 4°C overnight against 
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storage buffer (10% glycerol, 0.15 M NaCl, 5 mM β-mercaptoethanol, 50 mM HEPES, pH 7.5), 
followed by storage of samples at -80°C. 
To induce expression of N-terminally His6-tagged ubiquitin (His6-Ub) expression, 
pJO591 (Table S2) was transformed into BL21 (DE3) E. coli. 5 ml of overnight culture of 
transformed cells was inoculated into 0.4 l of LB medium containing 34 μg/ml chloramphenicol 
and 100 μg/ml ampicillin, followed by incubation at 37 °C for ~1 h to A600 of ~0.6. Expression of 
His6-Ub was induced with 1 mM isopropyl-D-thiogalactoside (IPTG) at 22°C overnight. Cells 
were harvested, thereafter, by centrifugation and frozen at -80°C. To overexpress N-terminally 
His6-tagged Ubc4 (His6-Ubc4), pJO589 (Table S2) was transformed into BL21 (DE3) E. coli. At 
A600 of ~0.5, IPTG was added to 1.6 l culture to the final IPTG concentration of 1 mM, followed 
by incubation at 37°C for 4 hr. N-terminally His6-tagged Rad6 (His6-Rad6) was similarly 
overexpressed from E. coli BL21 (DE3) transformed with pJO663 by adding 1 mM IPTG to 
400 ml of culture at A600 of 0.6, then incubated overnight at 22 °C (Table S2). 
His6-Ub and other His6-tagged overexpressed proteins were purified using TALON 
affinity resin (Clontech) as described in the manufacturer’s protocol, with slight modifications. 
Briefly, 3-4 g of cell pellet were resuspended in 40 ml of xTractor buffer containing 1×protease 
inhibitor cocktail (“for bacterial cells”; Sigma) 1×PMSF, 1×DNase I, and 40 mg lysozyme, 
followed by gentle shaking for 20 min at 4°C. After centrifugation at 12,000g for 20 min at 4°C, 
the supernatant was transferred to a 50-ml tube containing 1 ml of pre-washed TALON resin. 
After gentle shaking at 4°C for 1 hr, the slurry was transferred to a 10-ml polypropylene column, 
followed by two washes with equilibration buffer, one wash with wash buffer, and the elution of 
proteins with 10 ml of elution buffer (Clontech).  
His6-Rad6 purification was done as described above, except that before the elution step, 
the TALON-bound His6-Rad6 was incubated, at 4°C overnight, in 0.5 ml of the cleavage buffer 
(0.15 M NaCl, 1 mM EDTA, 1 mM DTT, 0.05% NP-40, 50 mM Tris-HCl, pH 8.0) containing 
30 μl of HRV 3C protease (Thermo Fisher). The resulting flow-through (the released His6-Rad6) 
was changed to equilibration buffer using PD-10 column (GE Healthcare). The sample was 
incubated, then, with 0.5 ml of Talon resin at 4°C for 1 hr and the flow-through was collected. 
Final protein samples were dialyzed against storage buffer (10% glycerol, 0.15 M NaCl, 5 mM 
β-mercaptoethanol, 50 mM HEPES, pH 7.5) overnight, followed by storage at -80°C. 
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In vitro ubiquitylation assay. Purified proteins for the assay were produced as described 
above. Purified S. cerevisiae Uba1 (Ub-activating enzyme, E1) was purchased from Boston 
Biochem. Purified SL-Chk1m−f
1−527 or SL-Chk1m−f
1−502 (5 μM) were incubated at 30°C for 15 min in 
the total volume of 20 μl containing 4 mM ATP, 0.15 M NaCl, 5 mM MgCl2, 1 mM DTT, 50 
mM HEPES, pH 7.5, as well as 80 μM (1.6 nmoles) His6-Ub and 0.1 μM (2 pmoles) Uba1. The 
assay also contained conditionally added (in several combinations) 1 μM (20 pmoles) Rad6 
and/or purified fUbr1 (final concentration 0.2 μM (4 pmoles)), and/or purified Ufd4f (final 
concentration 0.2 μM (4 pmoles)). All reaction components except Uba1 were mixed together on 
ice for 10 min, followed by the addition of Uba1. Reactions were carried out at 30°C and 
terminated by adding 8 μl of 4×LDS/PAGE loading buffer (Invitrogen). One half of each sample 
(14 μl) was heated at 95°C for 5 min, followed by 4-12% NuPAGE and immunoblotting with 
anti-c-myc antibody (Sigma). 
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Fig. S1. Substrate specificities and subunit compositions of S. cerevisiae Nt-acetylases. Older 
names of specific subunits are in parentheses. See the main text and references therein.  
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Fig. S2. Accelerated degradation of Chk1 in naa10Δ cells requires both Ubr1 and Ufd4. 
(A) Lane 1, blue stars denote 25, 37, 50, and 75 kDa markers, respectively. CHX-chases, 
using PRT (Figure 2B), with wt SL-Chk13f, for 0, 1 and 2 hr, with wild-type (wt) (lanes 2-4), 
naa10Δ (lanes 5-7), ubr1Δ (lanes 8-10), naa10Δ ubr1Δ (lanes 11-13), and doa10Δ ubr1Δ 
(lanes 14-16) S. cerevisiae. Extracts were prepared from cells withdrawn at indicated times of a 
chase. Proteins in an extract were fractionated by SDS-PAGE, followed by immunoblotting with 
anti-flag and anti-ha antibodies. The bands of Chk13f and fDHFRha are indicated.  
(B) 35S-pulse-chases, using PRT (Figure 2B), a 2-min pulse with 35S-Met/Cys, and a 
CHX-chase afterward, with wt SL-Chk13f, for 0, 20 and 60 min, in wt (lanes 1-3), naa10Δ 
(lanes 4-6), ubr1Δ (lanes 7-9), and naa10Δ ubr1Δ (lanes 10-13) S. cerevisiae. Extracts were 
prepared from cells withdrawn at indicated times of a chase, followed by precipitation of 
proteins with anti-flag magnetic beads, SDS-PAGE, and autoradiography. 
(C) Lane 1, kDa markers. CHX-chases, using PRT (Figure 2B), with wt SL-Chk13f, for 
0, 1 and 2 hr, with wt (lanes 2-4), naa10Δ (lanes 5-7), ubr1Δ (lanes 8-10), naa10Δ ubr1Δ 
(lanes 11-13), ufd4Δ (lanes 14-16), and naa10Δ ufd4Δ (lanes 17-19) S. cerevisiae. The bands of 
Chk13f and fDHFRha are indicated.  
(D) Quantification of data in C. For curve designations, see the lower part of C. All 
chases in this study were performed at least twice, yielding results that differed by less than 10%. 
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(E) Lane 1, blue stars denote 20, 25, 37, 50, and 75 kDa markers, respectively. 
CHX-chases, using PRT (Figure 2B), with the SD-Chk13f mutant, for 0, 1 and 2 hr, with wt 
(lanes 2-4), naa10Δ (lanes 5-7), ubr1Δ (lanes 8-10), and naa10Δ ubr1Δ (lanes 11-13) 
S. cerevisiae. The bands of the SD-Chk13f mutant and fDHFRha are indicated.  
(F) Lane 1, blue stars denote 25, 37, 50, and 75 kDa markers, respectively. CHX-chases, 
using PRT (Figure 2B), with the SR-Chk13f mutant, for 0, 1 and 2 hr, with wt (lanes 2-4), 
naa10Δ (lanes 5-7), ubr1Δ (lanes 8-10), and naa10Δ ubr1Δ (lanes 11-13) S. cerevisiae. The 
bands of the SR-Chk13f mutant and fDHFRha are indicated.  
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Fig. S3. Faster degradation of Chk1 in cells containing lower levels of Hsp90. 
(A) Lane 1, blue stars denote 20, 25, 37, 50, and 75 kDa markers, respectively. 
CHX-chases, using PRT (Figure 2B), with wt SL-Chk13f, for 0, 1 and 2 hr, with wt (lanes 2-4), 
naa10Δ (lanes 5-7), ubr1Δ (lanes 8-10), naa10Δ ubr1Δ (lanes 11-13), hsc82Δ (lanes 14-16), and 
hsp82Δ (lanes 14-16) S. cerevisiae. Extracts were prepared from cells withdrawn at indicated 
times of a chase. Proteins in an extract were fractionated by SDS-PAGE, followed by 
immunoblotting with anti-flag and anti-ha antibodies. The bands of Chk13f and fDHFRha are 
indicated.  
(B) Quantification of data in A. For curve designations, see the lower part of A. All 
chases in this study were performed at least twice, yielding results that differed by less than 10%. 
(C) Ubr1-mediated degradation of the endogenous wt SL-Chk1, C-terminally tagged 
(at the endogenous CHK1 gene) with myc epitopes (Chk19m). Lane 1, kDa markers. CHX-chases 
with wt endogenous Chk19m, for 0, 1 and 2 hr, with wt (lanes 2-4), naa10Δ (lanes 5-7), and 
ubr1Δ (lanes 8-10) S. cerevisiae. With immunoblots of tubulin as a loading control. 
(D) Quantification of data in C. For curve designations, see the lower part of C. All 
chases in this study were performed at least twice, yielding results that differed by less than 10%. 
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(E) Degradation of Tup1. Lane 1, kDa markers. CHX-chases, using PRT (Figure 2B), 
with the wt Tup13f protein (see the main text) for 0, 1 and 2 hr, with wt (lanes 2-4), naa10Δ 
(lanes 5-7), and ubr1Δ (lanes 8-10) S. cerevisiae. The bands of Tup13f and fDHFRha are 
indicated.  
(F) Degradation of Kar4. Same as in E but with the wt Kar43f protein (see the main text). 
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Fig. S4. Use of split-ubiquitin assays to analyze Chk1-Ubr1 and Chk1-Hsc82 Interactions. 
(A) Split-Ub-based fusions of Ubr1 vs. full-length Chk11-527 (see the legend to the main 
Figure 6 for additional details) in wt S. cerevisiae. A1 and A2, either Ubr1 alone or Chk1 alone 
(negative controls). A3, split-Ub assay with both Chk1 and Ubr1. Expression of HIS3 (the 
ultimate readout of split-Ub assay), in otherwise His- cells, was a function of affinity between 
test proteins. Left panels in A-C are images of His-containing plates, on which all yeast strains 
grew. His-lacking plates, on which only His+ cells grew, are on the right (see STAR Methods). 
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(B) Chk1-Ubr1 and Chk1-Hsc82 interactions. B1, Split-Ub assay with split-Ub-based 
fusions of full-length Chk1 vs. full-length Ubr1 in wt cells. B2, same as in B1 but in naa10Δ 
cells. B3, split-Ub assay, in wt cells, with split-Ub-based fusions of Chk1 vs. Hsc82, in which the 
CUb-activator moiety was located at the N-terminus of the Hsc82 moiety. B4, same as in B3, 
except that the CUb-activator moiety was located at the C-terminus of the Hsc82 moiety. Note a 
dramatically smaller split-Ub signal. 
(C) Split-Ub assays with Chk1 and Hsc82 in wt vs. naa10Δ cells. C1, Split-Ub assay, in 
wt cells, with Hsc82 alone (negative control). C2, Hsc82 vs. Chk1, in wt cells. C3, same as C2 
but in naa10Δ cells (see also the main Figure 6C). Note the near-absence of split-Ub signal in 
naa10Δ cells (C3), in contrast to wt cells (C2). 
(D) Immunoblotting-based comparison of the levels of the endogenous (untagged) 
S. cerevisiae Hsc82+Hsp82 in wt and mutant backgrounds using an antibody that recognizes 
both Hsc82 and Hsp82 (these highly similar proteins practically co-migrated upon SDS-PAGE 
under conditions used). Lane 1, blue stars denote 50, 75 and 100 kDa markers, respectively. 
Lanes 2-7, Hsc82+Hsp82 in wt, naa10Δ, ubr1Δ, naa10Δ ubr1Δ, hsc82Δ, and hsp82Δ 
S. cerevisiae. With immunoblots of tubulin as a loading control. 
(E) Quantification of data in D, with the level of Hsc82+Hsp82 in wt cells taken as 100%. 
All immunoblotting analyses in this study were performed at least twice, yielding results that 
differed by less than 10%. 
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Fig. S5. The known components of the S. cerevisiae Hsp90 system, save for Sgt1, are either 
identified or predicted substrates of the NatA (Naa10) Nt-acetylase. See also Fig. S1, the main 
text, and references therein. 
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Fig. S6. Ablation of Hsp90 cochaperones can destabilize Chk1. 
(A) Lane 1, kDa markers. Tetracycline (Tc)-based chases, using PRT (Figure 2B), with 
wt SL-Chk13f, for 0, 1, 2, and 4 hr, with wt (lanes 2-5), naa10Δ (lanes 6-9), sba1Δ (lanes 10-13), 
sse1Δ (lanes 14-17), sti1Δ (lanes 18-21), and tah1Δ (lanes 22-25) S. cerevisiae. Extracts were 
prepared from cells withdrawn at indicated times of a chase. Proteins in an extract were 
fractionated by SDS-PAGE, followed by immunoblotting with anti-flag and anti-ha antibodies. 
The bands of Chk13f and fDHFRha are indicated.  
(B) Quantification of data in A. For curve designations, see the right part of A. All chases 
in this study were performed at least twice, yielding results that differed by less than 10%. 
(C) Tetracycline (Tc)-based chases, using PRT (Figure 2B), with wt SL-Chk13f, for 
0, 1, 2, and 4 hr, with wt (lanes 1-4), naa10Δ (lanes 5-8), ubr1Δ (lanes 9-12), and naa10Δ ubr1Δ 
(lanes 13-16) S. cerevisiae. 
(D) Degradation of Gpd1. Lane 1, kDa markers. CHX-chases, using PRT (Figure 2B), 
with wt Gpd13f, for 0, 1, and 2 hr, with wt (lanes 2-4), naa10Δ (lanes 5-7), ubr1Δ (lanes 8-10), 
and naa10Δ ubr1Δ (lanes 11-13) S. cerevisiae. The bands of Gpd13f  and fDHFRha are indicated.  
  
18 
 
 
 
 
Fig. S7. Degradation of Ste11 and Hsc82 by the Arg/N-end rule pathway in naa10Δ cells. 
(A) Degradation of Ste11. Lane 1, blue stars denote 20, 25, 37, 50, 75 and 100 kDa 
markers, respectively. Tetracycline (Tc)-chases, using PRT (Figure 2B), with wt Ste113f, were 
for 0, 20, 60, and 120 min with wt (lanes 2-5), naa10Δ (lanes 6-9), and ubr1Δ (lanes 10-12) 
S. cerevisiae. Extracts were prepared from cells withdrawn at indicated times of a chase. Proteins 
in an extract were fractionated by SDS-PAGE, followed by immunoblotting with anti-flag and 
anti-ha antibodies. The bands of Ste113f (see the main text) and fDHFRha are indicated.  
(B) Quantification of data in A. For curve designations, see the lower part of A. All 
chases in this study were performed at least twice, yielding results that differed by less than 10%. 
(C) Degradation of Hsc82. Tetracycline (Tc)-chases, using PRT (Figure 2B), with wt 
Hsc823f, were for 0, 1, 2, 4, and 8 hr, with wt (lanes 2-5), naa10Δ (lanes 6-9), and ubr1Δ 
(lanes 10-13) S. cerevisiae. 
(D) Quantification of data in C. For curve designations, see the lower part of C. All 
chases in this study were performed at least twice, yielding results that differed by less than 10%. 
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Fig. S8. Mapping Chk1 degron by degradation assays. 
(A) A set of C-terminal truncations of the 527-residue Chk1. As indicated on the right 
(see also the main text), only SL-Chk13f
1−502 and SL-Chk13f
1−465 (in addition to the full-length 
SL-Chk13f
1−527; see, e.g., Figure 2C) could be expressed at readily detectable levels in 
reference-based PRT assays (Figure 2B). A yellow rectangle in the diagram of the full-length 
SL-Chk13f
1−527 denotes the 25-residue C-terminal segment of Chk1 that contains the bulk of its 
Ubr1-specific degron (see the main text). 
(B) Lane 1, kDa markers. CHX-chases, using PRT (Figure 2B), with the SL-Chk13f
1−502 
derivative of the full-length Chk1, for 0, 1, and 2 hr, with wt (lanes 2-4), naa10Δ (lanes 5-7), and 
ubr1Δ (lanes 8-10S. cerevisiae. The bands of SL-Chk13f
1−502 and fDHFRha are indicated.  
(C) Same as in B but with SL-Chk13f
1−465. 
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Table S1. E. coli and S. cerevisiae strains used in this study. 
Strains Relevant genotypes Sources 
E. coli strains: 
DH5a 
 
F– Φ80lacZΔM15 Δ(lacZYA-argF) 
U169 recA1 endA1 hsdR17 (rK–, mK+) phoA supE44 
λ– thi-1 gyrA96 relA1 
 
Invitrogen 
BL21-
CodonPlus(DE3)-
RIL 
F– ompT hsdS(rB – mB – ) dcm+ Tetr gal λ(DE3) 
endA Hte [argU ileY leuW Camr ] 
Stratagene 
STBL2 F– endA1 glnV44 thi-1 recA1 gyrA96 relA1 Δ(lac-
proAB) mcrA Δ(mcrBC-hsdRMS-mrr) λ– 
Invitrogen 
S. cerevisiae 
strains: 
BY4742 MATα his3-1 leu2-0 lys2-0 ura3-0 can1-100 Open Biosystems 
CHY271 naa10∆::KanMX6 in BY4742 Open Biosystems 
CHY272 naa30∆::KanMX6 in BY4742 Open Biosystems 
CHY273 naa20∆::KanMX6 in BY4742 Open Biosystems 
JOY499 sse1∆::KanMX6 in BY4742 Open Biosystems 
JOY4501 hsc82∆::KanMX6 in BY4742 Open Biosystems 
JOY4502 hsp82∆::KanMX6 in BY4742 Open Biosystems 
JOY544 sti1∆::KanMX6 in BY4742 Open Biosystems 
JOY545 tah1∆::KanMX6 in BY4742 Open Biosystems 
AH109 
 
MATa, trp1-901, leu2-3, 112, ura3-52, his3-200, 
gal4∆, gal80∆, LYS2::GAL1UAS-GAL1TATA-HIS3, 
GAL2UAS-GAL2TATA-ADE2, URA3::MEL1UAS-
MEL1TATA-lacZ 
Clontech 
NMY51 
 
MATa trp1 leu2 his3 ade2 LYS2::lexA-HIS3 
ade2::lexA-ADE2 URA3::lexA-lacZ 
Dualsystems 
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CHY346 ubr1∆::KanMX6, doa10∆::HphNT1 in BY4742 Lab collection 
CHY347 ubr1∆::KanMX6, naa10∆::HphNT1 in BY4742 Lab collection 
SC295 MAT a ura3-52 leu2-3, 112 reg1-501 gal1 pep4-3 Lab collection 
JOY379 ubr1∆::HphNT1 in BY4742 This study 
JOY439 cup9∆::NatNT2 in BY4742 This study 
JOY440 naa10∆::KanMX6, cup9∆::NatNT2 in BY4742 This study 
JOY441 
 
ubr1∆::KanMX6, naa10∆::HphNT1, cup9∆::NatNT2 
in BY4742 
This study 
 
JOY442 ufd4∆::HphNT1 in BY4742 This study 
JOY443 naa10∆::KanMX6, ufd4∆::HphNT1 in BY4742 This study 
JOY468 sba1∆::HphNT1 in BY4742 This study 
JOY487 pdr5∆::NatNT2 in BY4742 This study 
JOY498 naa10∆::KanMX6, pdr5∆::NatNT2 in BY4742 This study 
JOY505 naa10∆::KanMX6 in NMY51 This study 
JOY512 CHK1-9myc::HphNT1 in BY4742 This study 
JOY513 CHK1-9myc::HphNT1, naa10∆::KanMX6 in BY4742 This study 
JOY514 CHK1-9myc::KanMX4, ubr1∆::HphNT1 in BY4742 This study 
JOY529 naa10∆::KanMX6, ubr1∆::HphNT1 in NMY51 This study 
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Table S2. Plasmids used in this study. 
Plasmid Description Source or Reference 
pDHB1 Split-Ub assay bait vector. Contains the PCYC1 
promoter. Used to produce Ost4-Cub-LexA-VP16 
fusion. 
Dualsystems 
pPR3-N Split-Ub assay prey vector. Contains the PCYC1 
promoter. Produces NubG–HA fusion. 
Dualsystems 
pDONR/Zeo Donor vector for Gateway cloning through BP 
reaction. 
Invitrogen 
pGADCg Y2H expression vector. Contains the PADH1 
promoter. Used to produce C-terminal Gal4-ADha* 
fusion by Gateway cloning. *contains a partial ha 
epitope sequence. 
Addgene 
pGBKT7g Y2H expression vector. Contains the PADH1 
promoter. Produces N-terminal Gal4-DBDmyc fusion 
by Gateway cloning. 
Addgene 
pDONR/Zeo Donor vector for Gateway cloning via BP reaction Invitrogen 
pET-11d pET-11d Novagen 
pET-15b pET-15b Novagen 
pFA6a-
KanMX6 
pFA6a-KanMX6 (19) 
pFA6a-
HphNT1 
pFA6a-HphNT1 (6) 
pFA6a-
NatNT2 
pFA6a-NatNT2 (6) 
pTDH3-tc3-
3×HA 
PTDH3-tc3-3×HA (7) 
pRS313  pRS313 (20) 
pRS314 
Gal1/10 
pRS314 with PGAL1/10 (20) 
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pRS413 
Met25 
pRS413 with PMET25 (20) 
pRS425 Gal1 pRS425 with PGAL1 promoter (20) 
pYM18 9 c-Myc with KanMX4  (6) 
pYM20 9 c-Myc with HphNT1  (6) 
pNTfUBR1 flagUbr1 in YEPlac181 (21) 
pUsp2-cc Usp21-45 ORF in pET-15b (3) 
pHUE His6-Ub fusion in pET-15b (3) 
pJO162 Naa10 in pH10UE This study 
pJO241 pRS426 with PGAL1/10 This study 
pJO267 Naa10 in pRS425 Gal1/10 This study 
pJO379 MK-eK-haha-Ura3-Ub-flagDHFRha in pRS413 Gal1 This study 
pJO589 His6-Ubc4 in pET-15b This study 
pJO591 His6-Ub in pET-15b This study 
pJO622 PTDH3-tc3 and flagDHFRha in pRS413  This study 
pJO624 Complete set of PRT vector with MAI-Cln3 in 
pRS313 
This study 
pJO630 MSL-Chk1 in pJO624 This study 
pJO638 MSA-Gpd1 in pJO624 This study 
pJO639 MTA-Tup1 in pJO624 This study 
pJO641 MSD-Chk1 in pJO630 This study 
pJO642 MSK-Chk1 in pJO630 This study 
pJO643 MSP-Chk1 in pJO630 This study 
pJO644 MSR-Chk1 in pJO630 This study 
pJO645 MSF-Chk1 in pJO630 This study 
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pJO661 MPS-Chk1 in pJO630 This study 
pJO663 His6-HRV 3C protease site-Rad6 in pET-11d This study 
pJO679 Ufd4flag in pRS425 Gal1 This study 
pJO684 MAI-Cdc37 in pJO624 This study 
pJO689 flagUbr1 in pRS426 Gal1/10 This study 
pJO690 Ufd4hsv and flagUbr1 in pRS426 Gal1/10 This study 
pJO691 MAG-Hsc82 in pJO624 This study 
pJO695 PTDH3-tc3 and P-flagDHFRha in pRS413 This study 
pJO697 Chk11-527 in pJO699 This study 
pJO699 PTDH3-tc3 and P-flagDHFRha in pJO624 This study 
pJO723 Chk11-480 in pJO699 This study 
pJO724 Chk11-422 in pJO699 This study 
pJO725 Chk11-360 in pJO699 This study 
pJO726 Chk-11-300 in pJO699 This study 
pJO727 Chk11-180 in pJO699 This study 
pJO732 Chk11-502 in pJO699 This study 
pJO733 Chk11-465 in pJO699 This study 
pJO734 Chk11-414 in pJO699 This study 
pJO735 Chk11-377 in pJO699 This study 
pJO736 MAF- Kar4 in pJO699 This study 
pJO746 PCUP1-DHFR-ha-Ub
K48-Y-eK-βgal in pRS313 This study 
pJO747 PCUP1-DHFR-ha-Ub
K48-H-eK-βgal in pRS313 This study 
pJO752 UbK48-Y-eK βgal in pJO699 This study 
pJO753 UbK48-H-eK βgal in pJO699 This study 
pJO781 attL-Ubr1 in pDONR/Zeo This study 
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pJO794 SV40-NLS-Ubr1-Gal4-AD in pGADCg This study 
pJO829 Chk11-527myc-flag in pRS423 This study 
pJO830 Chk11-502myc-flag in pRS423 This study 
pJO841 Ost4-Chk1-CUb-LexA-VP16 in pDHB1 This study 
pJO842 NUb-Chk1
1-527 in pPR3-N This study 
pJO858 NUb-Chk1
1-502 in pPR3-N This study 
pJO859 NUb-Chk1
1-510 in pPR3-N This study 
pJO860 NUb-Chk1
1-517 in pPR3-N This study 
pJO862 Ost4-Hsc82-CUb-LexA-VP16 in pDHB1 This study 
pJO863 NUb-Hsc82 in pPR3-N This study 
pJO898 MEQ-Ste11 in pJO624 This study 
pJO903 Ost4-flagUbr1-CUb-LexA-VP16 in pDHB1 This study 
pJO930 attL-Chk11-527 in pDONR/Zeo This study 
pJO931 attL-Chk11-502 in pDONR/Zeo This study 
pJO932 attL-Chk11-465 in pDONR/Zeo This study 
pJH024 Gal4-DBDmyc-Chk1
1-527 in pGBKT7g This study 
pJH028 Gal4-DBDmyc-Chk1
1-502 in pGBKT7g This study 
pJH030 Gal4-DBDmyc-Chk1
1-465 in pGBKT7g This study 
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